Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology. The content featured in this issue specifically addresses the evaluation and recommended treatment options outlined in the NCCN Guidelines for the diverse subtypes of cancer-associated VTE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
Blom, J. W. (2005) · JAMA · doi:10.1001/jama.293.6.715 · Cited by 1,949
Decousus, H., Leizorovicz, A., Parent, F., Page, Y., Tardy, B., Girard, P., Laporte, S., Faivre, R., Charbonnier, B., Barral, F.-G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380701 · Cited by 1,702
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Kucher, N., Boekstegers, P., Müller, O. J., Kupatt, C., Beyer-Westendorf, J., Heitzer, T., Tebbe, U., Horstkotte, J., Müller, R., Blessing, E., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005544 · Cited by 1,151 · cited 1×
“128 Larger randomized studies with clinical outcomes areneededtocon fi rmthebene fi tsofthisapproach.”
Transcatheter Thrombolytic Therapy for Acute Mesenteric and Portal Vein Thrombosis
Hollingshead, M., Burke, C. T., Mauro, M. A., Weeks, S. M., Dixon, R. G., & Jaques, P. F. (2005) · Journal of Vascular and Interventional Radiology · doi:10.1097/01.rvi.0000156265.79960.86 · Cited by 314
Portal vein thrombosis; risk factors, clinical presentation and treatment
Sogaard, K. K., Astrup, L. B., Vilstrup, H., & Gronbaek, H. (2007) · BMC Gastroenterology · doi:10.1186/1471-230x-7-34 · Cited by 217 · cited 2×
“168,171 Weight loss, abdominal distension, and postprandial abdominal pain may also be associated with chronic mesenteric vein thrombosis.”
Survival and Recurrence in Patients With Splanchnic Vein Thromboses
Thatipelli, M. R., McBane, R. D., Hodge, D. O., & Wysokinski, W. E. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.09.019 · Cited by 201 · cited 1×
“142 In chronic SPVT, the presence of portal hypertension may increase the risk of bleeding from esophageal varices and splenomegaly may lead to decreased platelet counts, which can further increase the risks of bleeding events in patients treated with anticoagulation.”
Dentali, F., Squizzato, A., Brivio, L., Appio, L., Campiotti, L., Crowther, M., Grandi, A. M., & Ageno, W. (2009) · Blood · doi:10.1182/blood-2008-12-196014 · Cited by 176
Mesenteric venous thrombosis with transmural intestinal infarction: A population-based study
Acosta, S., Ögren, M., Sternby, N.-H., Bergqvist, D., & Björck, M. (2005) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2004.10.011 · Cited by 96 · cited 1×
“141,144 Risk Factors Risk factors for SPVT relevant to patients with cancer include recent abdominal surgery (eg, splenectomy), 146 – 149 abdominal mass, pancreatitis, 150 cirrhosis, 143 paroxysmal nocturnal he-moglobinuria (PNH), 151 myeloproliferative disorders, 152 and JAK2V617F mutation with or…”
Ageno, W., Witt, D., Malato, A., Clark, N., Garcia, D., McCool, K., Siragusa, S., Dyke, S., Crowther, M., Dentali, F., et al. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-12-0842 · Cited by 61
Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis
Candeloro, M., Valeriani, E., Monreal, M., Ageno, W., Riva, N., Lopez-Reyes, R., Peris, M. L., Beyer Westendorf, J., Schulman, S., Rosa, V., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007961 · Cited by 36 · cited 1×
“177 The study did include patients with cancer (32% of patients had solid cancers, 7.2% had myeloproliferative neoplasms, and 1.2% had leukemia, lymphoma, or multiple myeloma).”
Influential
Metadata
- Authors
- Streiff, M. B., Holmstrom, B., Angelini, D., Ashrani, A., Buckner, T., Diep, R., Fertrin, K. Y., Fogerty, A. E., Crestani, N. G., Gangaraju, R., Rojas-Hernandez, C., Goldhaber, S. Z., Ibrahim, I., Kubal, T., Leavitt, A. D., Lim, M., Mann, J., Mantha, S., Morton, C., Nester, A., O’Brien, A., Ortel, T. L., Pine, A., Pishko, A., Ranade, M., Salmasi, A., Schaefer, J., Williams, E., Wool, G., Wun, T., Montgomery, S., Nguyen, J., Freedman-Cass, D., & Sliker, B.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2024-09
- Volume
- 22
- Issue
- 7
- Pages
- 483-506
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W4402261051
- Cited by
- 184
- References
- 15
- FWCI
- 49.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.